Background: Prader-Willi syndrome (PWS) is associated with hyper-
Introduction
Prader-Willi syndrome (PWS) occurs in 1:15 000 to 1:30 000 births worldwide (1) because of loss of the paternal allele at 15q11.2-13 (2) . Between birth and 2 years, affected children typically manifest hypotonia, delayed motor development and failureto-thrive. After this age, an insatiable appetite and progressive obesity ensue (3) . Major morbidity and mortality in PWS are because of complications from uncontrolled obesity (4) . Relentless food-seeking behaviour in PWS can be disruptive to home and school activities, causing families social and psychological turmoil. Currently, there is no effective medical therapy of hyperphagia in individuals with PWS.
PWS's obesity phenotype is unique, including delayed meal termination, earlier return of hunger, increased food consumption, hoarding and stealing of food, pica, delayed gastric emptying and reduced vomiting (5, 6) . Decreased resting energy expenditure compared with the general population leads to weight gain without appropriate food restriction (7) . Weight control is difficult, and current treatment includes behavioural modifications, calorie reduction, exercise, close supervision and restriction from food and money (8) . Although the aetiology of hyperphagia in PWS is not fully elucidated, it has been postulated that the distinctive hyperghrelinemia in PWS is related to their obesity. Ghrelin is an orexigenic hormone produced predominantly in the stomach with circulating concentrations normally elevated when fasting and decreased after eating. Elevated ghrelin levels in rodents and humans are associated with increased appetite, food consumption and weight gain (9, 10) . Multiple studies show elevated plasma ghrelin levels in subjects with PWS at all ages (11) (12) (13) (14) . As hyperphagia seems to be the primary basis of obesity in PWS, therapy targeting components underlying hyperphagia is needed to alleviate the burden of obesity in PWS.
Exenatide [Byetta ™ ; AstraZeneca, Wilmington DE] is a GLP-1 receptor agonist and incretin-mimetic FDA-approved as adjunctive treatment of type 2 diabetes in adults. In addition, exenatide has resulted in persistent weight loss in animals and obese adults with and without type 2 diabetes (15,16). Modest reductions in body mass index (BMI) in obese adolescents without diabetes on exenatide have been shown, although the same reduction was not seen in the placebo group during an open label extension (17) . Exendin-4 (exenatide) has decreased ghrelin levels up to 74% for a period of 8 h after administration to fasted rodents (18) . Additionally, in obese subjects, intravenous exenatide decreased hyperactivation of brain responses to food cues in areas associated with reward and appetite, suggesting a central mechanism in appetite regulation (19) . A case report showed successful weight loss in a female with PWS treated with exenatide (20) . Another study showed increased satiety in adults with PWS after a single dose of exenatide, with fewer side effects in PWS subjects than obese controls, although ghrelin levels were not affected (21) . Despite these promising data, there have been no published studies on long-term use of exenatide in a large population of individuals with PWS. To determine if exenatide decreases appetite and weight in subjects with PWS, we designed a pilot study to examine its effects in adolescents and young adults with PWS over a 6-month period.
Methods

Subjects
The study was conducted at Children's Hospital Los Angeles (CHLA). Potential subjects were identified from endocrinology clinics at CHLA and Children's Hospital of Orange County and through the PraderWilli Syndrome Association (http://www.pwsausa. org/). Enrollment criteria included the following: age 13-25 years, BMI ≥ 85th percentile for subjects <18 years or ≥25 kg m À2 for subjects ≥18 years, genetic confirmation of PWS. Subjects were excluded if they had the following: previously used GLP-1 receptor agonists, other syndromic illness, prior medical or family history of pancreatitis or renal failure, change in doses of testosterone, estrogen, or growth hormone > 25% of dose/kg/day within the past 6 months. No subjects were on appetite or weight altering medications other than metformin in those with type 2 diabetes. Once consented, subjects were seen for an initial screening visit, which included review of past medical history, physical examination and safety laboratory tests (comprehensive metabolic profile, amylase, lipase and serum hCG if female). Ten subjects (four male/six female, age range 14.7-24.6 years, age mean 18 years, and age median 16 years) were recruited (Fig. 1) . Race of subjects were as follows: six non-Hispanic white, one nonHispanic black, one Mexican-American and two other or mixed race. Nine subjects completed the study, and one subject withdrew after 1 month because of transportation difficulties. Three subjects (including withdrawal subject) had type 2 diabetes at enrollment. Diabetes medication doses (rapidacting insulin, long-acting insulin and metformin) were stable at least 3 months prior to enrollment, and no changes were made during the study. Reasons for refusal to enroll in the study included the following: difficulty with travel (n = 2), unwillingness to participate in research (n = 6) and unwillingness to take injectable medications (n = 1).
Study procedures
The study protocol was approved by the Committee on Clinical Investigations, the institutional review board of CHLA and registered on clinicaltrials.gov (NCT01444898) prior to enrollment. Signed parental consents and age-appropriate assents were obtained. Study visits occurred at baseline, and 1, 3 and 6 months after starting exenatide, each in the morning after > 8-h fast. Each visit included a history, physical examination, appetite questionnaire and safety-and obesity-related laboratory tests (hemoglobin A1c [HbA1c], insulin, acylated ghrelin, leptin and pancreatic polypeptide [PP] ). Standing heights (without shoes) were determined at each visit using a digital wall-mounted stadiometer, accurate to within 0.1 cm, and weight was measured using a digital scale to the nearest 0.1 kg, with the subjects in light clothing.
At baseline and 6-month visits, subjects underwent a mixed meal tolerance test (MMTT). Boost® was given at 6 mL kg À1 up to 360 mL. Blood was drawn for glucose, acylated ghrelin and PP measurements at baseline (fasting) and +15, +60, and +120 min. Dual X-ray absorptiometry evaluation for body composition was performed at baseline and 6 months (Hologic Delphi W Bone Densitometer [Bedford, MA]). Truncal fat was analysed as total body fat was unable to be measured accurately in subjects larger than scan perimeters.
As subjects had adult weights >69 kg at baseline, standard FDA-approved adult diabetes dosing of exenatide was used; 5 mcg twice daily subcutaneous (SQ) injections by pen device was started on the evening of the baseline visit, increased to 10 mcg twice daily at the 1-month visit, and continued thereafter. Exenatide was given 60 min prior to morning and evening meals. Subjects received the dose of exenatide the evening prior to the 1-, 3-and 6-month study visits but not in the morning.
Hyperphagia questionnaire
A syndrome-specific validated hyperphagia questionnaire (22) was completed by the same caretaker familiar with the subject's daily routine. It was performed at the beginning of each visit, including those with a MMTT, and scored according to previously published guidelines. The scores were tallied as a total and sub-divided into behaviour, drive and severity components.
Study medication adherence
Subjects returned used pens at follow-up study visits, and adherence was inferred by calculating the percent of medication used. Categorization included high (≥80% medication used), moderate (50-80% medication used) and low (<50% medication used).
Assays
Comprehensive metabolic panel analytes, amylase, lipase, insulin (using chemiluminescent immunoassay), hCG and HbA1c were measured at Quest Laboratories (West Hills, CA) using commercially available assays. Acylated ghrelin, leptin and PP were measured using enzyme-linked immunosorbent assays (EMD Millipore, Billerica, MA). Samples for acylated ghrelin were collected in EDTA tubes containing 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, and hydrochloric acid was later added. Samples were stored at À80°C for batch analyses.
Safety monitoring
At each visit, adverse event monitoring was performed. Serum amylase and lipase levels were measured to evaluate pancreatic function. Renal function was monitored by calculating estimated creatinine clearance using the Cockcroft-Gault formula (23) .
Statistics
Prior to analysis, distributions were evaluated for normality and natural log transformation was performed to analyse data not normally distributed. Data are presented as mean ± SD unless not normally distributed, in which case they are presented as median with intra-quartile ranges (25th and 75th percentiles). Within-subject changes between visits were analysed by mixed model repeated measures. When the overall F-test for difference among visits was significant, Dunnett-adjusted pairwise comparisons were made between baseline and each subsequent visit. MMTT data were analysed both by linear mixed model measures as well as area-under-the-curve. Statistical analysis was performed with SAS/STAT® software v9.2 (Cary, NC).
Results
Anthropometrics and adiposity
Exenatide treatment was not associated with a significant change in mean weight, BMI or BMI z-score over time (Table 1, Fig. S1 ). There was no significant change in mean BMI percent change from baseline at 1 month (0.6% ± 1.8%, p = 0.4), 3 months (0.6% ± 2.9%, p = 0.5) or 6 months (1.3% ± 2%, p = 0.08). There was no significant change in adiposity from baseline as measured by dual X-ray absorptiometry. Mean baseline truncal fat was 20 ± 4.6 kg, and mean percent truncal fat was 46.3 ± 6.4%. Mean 6-month truncal fat was 19.3 ± 4.2 kg, and mean percent truncal fat was 44.7 ± 6.8% (p = 0.4 and 0.1, respectively).
Appetite scores
Total appetite scores significantly decreased from baseline (32.2 ± 8.7) after 1, 3 and 6 months of treatment (27.5 ± 8.8, 25.4 ± 9.3 and 25.4 ± 7.2 respectively; p = 0.004). This reduction was primarily driven by decreases in behaviour and drive subscores, as no significant difference in change of severity score was seen (Fig. 2) .
Obesity-related laboratory tests
There was a significant decrease in mean HbA1c from baseline after 1, 3 and 6 months of treatment. There was no significant change in fasting insulin, leptin, PP or acylated ghrelin from baseline at any visit (Table 1 ). There was no difference noted in MMTT results for visits 1 and 4 based on mixed model analyses for acylated ghrelin, PP or glucose (p-values 0.6, 0.8 and 0.9 respectively; data not shown). There was no difference in excursion of acylated ghrelin, PP or glucose during the MMTT based on area-under-thecurve data (p-values 0.5, 0.7 and 0.3 respectively; data not shown).
Safety laboratory test results and serious adverse events
All subjects had normal baseline amylase, lipase and creatinine with no significant change in levels after treatment. There were no serious adverse events during the study. One subject reported abdominal cramping and diarrhea for a short period because of acute infectious gastroenteritis. Another subject experienced mild abdominal discomfort and diarrhea after doubling the dose of exenatide for 1 d. There were no other reports of gastroenterological symptoms. 
Adherence and confounding factors
Examination of returned pens showed ≥70% high adherence, suggesting that non-adherence did not impact our results. However, we found multiple confounding factors during the study including change in eating schedule during the school year vs. vacation, use of psychotropic medications (one subject had adjustment of antidepressive medications), change in caretaker supervision and unforeseen orthopaedic procedures leading to decreased activity.
Discussion
This pilot study investigated the effects of exenatide on weight and appetite in overweight youths with PWS, in which we compared weight, BMI, adiposity and appetite scores over 6 months. We chose a medication-only intervention without incorporating diet or lifestyle modifications to evaluate if a therapy targeting hyperphagia would be a beneficial and safe option for weight control in individuals with PWS. We found a significant decrease in appetite scores, specifically in the behaviour and drive categories, which were noted as early as 1 month after initiation of treatment. Nonetheless, there was no effect on weight, BMI or adiposity over 6 months. We also measured circulating levels of acylated ghrelin, PP and leptin during treatment with exenatide. Hyperghrelinemia is well documented in PWS and is hypothesized to contribute to the hyperphagic state of the condition (11) (12) (13) (14) . Pancreatic polypeptide is an anorectic hormone released by the pancreas, and levels are normally lower in the fasting state and increase after eating. Studies have shown deficiency of PP in PWS, which may also contribute to hyperphagia (24, 25) . In our study, there was no significant change in acylated ghrelin or PP during treatment despite a decrease in appetite scores, which does not further elucidate the role these hormones may play in regulating appetite in PWS, suggesting that hyperphagia in this condition is multifactorial. We also considered that the lack of change may have been because of the waning effect of the evening dose of exenatide as concentrations are usually measurable for about 10 h. It may also be postulated that if effects wane between doses, fluctuations in appetite suppression may occur during the day. Longer-acting GLP-1 agonists may alleviate these difficulties. The one case report documenting the long-term effects of exenatide in an individual with PWS showed significant decrease in weight, but did not comment on the diet or exercise regimen during the treatment (20) . Two other case reports on the use of a longeracting GLP-1 receptor agonist, liraglutide, in patients with PWS (26, 27) showed significant weight loss after the initiation of treatment; however, only Senda et al. (27) discussed concomitant lifestyle modifications. A recent publication of six adults with PWS and type 2 diabetes treated with either exenatide or liraglutide showed a trend in improved BMI and glycaemic control over 24 months that was not statistically significant (28) . The combination of these reports as well as our findings suggests that there is a need to incorporate lifestyle modifications in addition to appetitesuppressing medication.
Similar to the previously mentioned case reports, we saw a significant decrease in HbA1c during treatment. This is an expected outcome of GLP-1 receptor agonists and highlights the additional benefit of improved glycaemic control with this class of medication and indicates good compliance during the course of the study.
In our small cohort, we found no evidence of safety concerns with exenatide use. The most commonly reported side effects are nausea, vomiting, diarrhoea, dizziness, headache, jitteriness and acidic stomach. During the study, we had one complaint of drug-related nausea and abdominal pain when a subject took twice the recommended dose. This suggests that exenatide is well tolerated in individuals with PWS, as previously suggested by Sze et al. (21) . In light of reports of pancreatitis, pancreatic cancer and pancreatic hyperplasia in individuals receiving GLP-1 receptor agonist therapy, we monitored for symptoms of pancreatic disease and measured levels of circulating pancreatic enzymes during treatment (29, 30) . We found no change in serum amylase or lipase levels. In addition, other studies have commented on a hypothetical increased risk of gastric rupture in individuals with PWS treated with exenatide because of delayed gastric emptying (21) . Accordingly, we counselled our subjects and caregivers about the symptoms and risk of gastric rupture. During the study, there were no complaints of symptoms associated with pancreatitis or gastric rupture. Thus, it appears that exenatide can be used safely in this population.
We recognize the limitations to our study, the first of which is our small sample size. It is challenging to recruit qualified subjects with a rare disorder, and with a larger sample size, we may have been able to detect a change in weight or adiposity. As our recruitment area was small, this may have created some referral bias although we did attempt to open recruitment to subjects outside of CHLA. We recognize that this study was not randomized or placebocontrolled. Also, the short length of our study may have impacted our ability to see weight loss and therefore a longer term study is needed. We did not attempt to introduce standardized lifestyle modifications. With the lack of scientific data on the efficacy and safety of exenatide in PWS, we felt it was prudent to start with a pilot study to see if further studies are warranted. As such, we also did not introduce lifestyle modifications which could themselves influence weight loss results and, rather, focused on the effects of the addition of only exenatide. In addition, we noted multiple confounding factors during the study, including variations in eating schedule, psychotropic medications, caretaker supervision and activity. Some of these factors were unavoidable, but others could be controlled for in future studies. The subjective collection of appetite measures may lead to inaccuracy of results and future studies should consider the addition of objective methods such as food intake measurement. With the decrease in appetite scores, a change in weight or adiposity would have been expected but the previously mentioned factors may have impacted our ability to detect change; therefore, future studies controlling for these limitations may yield different results. Despite these limitations, this is the first study to systematically examine the long-term effects of exenatide on weight and appetite in a group of subjects with PWS. However, it is clear that medication alone is not an effective method of controlling weight in PWS.
This 6-month pilot study of overweight and obese youths with PWS showed that exenatide was well tolerated and resulted in a significant decrease in appetite and HbA1c, but no decrease in weight, BMI, adiposity, acylated ghrelin or PP. Obesity in PWS is multifactorial and requires a multidimensional treatment strategy. Our findings suggest that larger, controlled studies are required to further study the efficacy and safety of exenatide in subjects with PWS. Longer-acting formulations of GLP-1 agonists may alleviate some of the challenges that limited our study and warrant further exploration.
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